Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma

被引：17

作者：

Kim, Chan ^{[1
]}

Yoo, Kwai Han ^{[2
]}

Kim, Min Hwan ^{[3
]}

Chon, Hong Jae ^{[1
]}

Lee, Soon Il ^{[4
]}

Lee, Hyo Jin ^{[5
]}

Koh, Sujin ^{[6
]}

Lee, Ha Yeon ^{[7
]}

Lee, Hye Ran ^{[8
]}

Kim, Kyung Sik ^{[9
]}

Choi, Young Deuk ^{[10
]}

Rha, Sun Young ^{[3
]}

Lee, Su Jin ^{[2
]}

Kim, Hyo Song ^{[3
]}

机构：

[1] CHA Univ, CHA Bundang Med Ctr, Med Oncol, Pangyo, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol & Oncol, Seoul, South Korea

[3] Yonsei Univ Coll Med, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, 50 Yonsei ro,Seodaemun, Seoul 150752, South Korea

[4] Dankook Univ, Coll Med, Dept Med, Div Hematol Oncol, Yongin, South Korea

[5] Chungnam Natl Univ, Sch Med, Dept Internal Med, Daejeon, South Korea

[6] Univ Ulsan Coll Med, Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea

[7] Kyunghee Univ Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea

[8] Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Div Hematol Oncol, Gimhae, South Korea

[9] Yonsei Univ Coll Med, Dept Surg, Seoul, South Korea

[10] Yonsei Univ Coll Med, Dept Urol, Seoul, South Korea

来源：

APMIS | 2017年 / 125卷 / 03期

关键词：

Epithelioid sarcoma; subtype; chemotherapy; radiotherapy; clinical outcome; MTOR;

D O I：

10.1111/apm.12656

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Epithelioid sarcoma (ES) is a very rare soft-tissue sarcoma with a high tendency of recurrence and metastasis. We analyzed clinical features of ES and aimed to identify the potential role of radio-and chemotherapy in ES. Fifty-five patients diagnosed with ES between 1997 and 2014 were enrolled from seven tertiary hospitals in Korean Cancer Research Group. The clinical variables were retrospectively reviewed and analyzed. Forty-six (84%) patients underwent surgical resection of ES, and among them, 27 experienced recurrence. In these patients, resection margin status and adjuvant radiotherapy were independent prognostic factors for longer recurrence-free survival (RFS), while adjuvant chemotherapy did not influence RFS. Twenty-two (40%) patients received palliative chemotherapy for metastatic or recurrent ES, and in these patients, palliative chemotherapy was the only independent prognostic factor for longer overall survival. Intriguingly, the clinical benefit of radio-and chemotherapy was observable only in proximal ES, but not in extremity ES, indicating that subtypes of ES might respond to radio-or chemotherapy differently. Proximal ES seems to benefits more from active anticancer treatment than conventional extremity ES. The aggressive characteristics of proximal ES could be overcome with an optimal multimodal treatment.

引用

页码：223 / 229

页数：7

共 22 条

[21] Epithelioid sarcoma: the University of Washington experience [J].

Wolf, Patrick S. ;

Flum, David R. ;

Tanas, Munir R. ;

Rubin, Brian P. ;

Mann, Gary N. .

AMERICAN JOURNAL OF SURGERY, 2008, 196 (03) :407-412

[22] Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma [J].

Xie, Xianbiao ;

Ghadimi, Markus P. H. ;

Young, Eric D. ;

Belousov, Roman ;

Zhu, Quan-sheng ;

Liu, Juehui ;

Lopez, Gonzalo ;

Colombo, Chiara ;

Peng, Tingsheng ;

Reynoso, David ;

Hornick, Jason L. ;

Lazar, Alexander J. ;

Lev, Dina .

CLINICAL CANCER RESEARCH, 2011, 17 (18) :5901-5912

← 1 2 3 →